Masoud Khorsand-Sahbaie, MD
Hematology & Oncology · Roswell, NMNPI 1629066097
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,099 of the $3,613 with a category attached, or 85.8%. It is spread thinly across 43 manufacturers, the largest accounting for just 10.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,222 and has fallen 66.3% since, to $411 in 2025.
Across 165 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$379
- Myriad Women's Health, Inc.$331
- Novartis$276
- E.r. Squibb & Sons, L.L.C.$233
- Merck$189
- Pfizer$158
- plus $2K from 37 others
What the payments were for
- Food & beverage$3,09986%
- Education$51414%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myRisk$331
- FOUNDATIONONE$133
- FOUNDATIONONE HEME$133
- FOUNDATIONONE CDX$133
- FOUNDATIONFOCUS$133
- FOUNDATIONONE LIQUID$133
How this compares
$3,613 in reported general payments places this provider in the 60th percentile of 54 hematology & oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 36 | $465,814 |
| SprycelDasatinib | 16 | $287,265 |
| PomalystPomalidomide | 12 | $280,766 |
| TasignaNilotinib Hcl | 15 | $266,712 |
| CalquenceAcalabrutinib Maleate | 14 | $210,635 |
| TafinlarDabrafenib Mesylate | 12 | $179,346 |
| LonsurfTrifluridine/Tipiracil Hcl | 11 | $110,197 |
| InlytaAxitinib | 11 | $75,978 |
| Imatinib Mesylate | 12 | $54,000 |
| EliquisApixaban | 40 | $36,652 |
| Abiraterone Acetate | 12 | $27,296 |
| XareltoRivaroxaban | 13 | $15,769 |
| Anastrozole | 131 | $1,827 |
| Morphine Sulfate | 33 | $1,386 |
| Morphine Sulfate ErMorphine Sulfate | 26 | $1,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Sprycel, Pomalyst | $233 | $568,03128 claims |
| NovartisTasigna, Tafinlar | $276 | $446,05827 claims |
| AstraZenecaCalquence | $128 | $210,63514 claims |
| PfizerInlyta, Eliquis | $158 | $112,63051 claims |
| Johnson & JohnsonXarelto | $142 | $15,76913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 54 hematology & oncology providers in New Mexico.
Other hematology & oncology in Roswell
- Elizabeth Guadalupe VallejoRoswell$3K
- Luis Gonzalez MosqueraRoswell$813
- Ursa Brown GlabermanAlbuquerque$219K
- Neda Hashemi SadraeiAlbuquerque$96K
- Muhammad TarakjiAlbuquerque$34K
- Yara AbdouAlbuquerque$25K
- Sardar ImamFarmington$24K
- George AtwehAlbuquerque$24K
- Ankit AnandFarmington$16K
- Ethan BinderRio Rancho$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.